Multiple etiologies should be considered in the differential diagnosis of immunocompromised patients with non–central nervous system cancer and viral infections who develop mutism. Acute cerebellitis, caused by infections or by neurotoxicity resulting from chemotherapy; paraneoplastic cerebellar degeneration; atypical posterior reversible encephalopathy syndrome; and acute disseminated encephalomyelitis may all cause mutism in such patients. This condition warrants prompt recognition and may require treatment with immunotherapy, as it may be an immune-mediated process. We present 2 patients with leukemia and viral illness who developed cerebellar mutism in the setting of acute cerebellitis and responded to immunotherapy, suggesting that the condition involved a parainfectious immune-mediated response.
RobertsonPLMuraszkoKMHolmesEJ. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children’s Oncology Group. J Neurosurg. 2006;105:444–451.
2.
PollackIFPolinkoPAlbrightALTowbinRFitzC. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery. 1995;37:885–893.
3.
De SmetHJBaillieuxHCatsman-BerrevoetsC. Postoperative motor speech production in children with the syndrome of “cerebellar” mutism and subsequent dysarthria: a critical review of the literature. Eur J Paediatr Neurol. 2007;11:193–207.
4.
LevisohnLCronin-GolombASchmahmannJD. Neuropsychological consequences of cerebellar tumour resection in children: cerebellar cognitive affective syndrome in a paediatric population. Brain. 2000;123:1041–1050.
5.
KohSTurkelSBBaramTZ. Cerebellar mutism in children: report of six cases and potential mechanisms. Pediatr Neurol. 1997;16:218–219.
6.
ErolIÖzkaleYSaygiSAlehanF. Cerebellar mutism caused by primary varicella infection in an immunocompetent child. J Child Neurol. 2014;29:830–832.
7.
DimovaPSBojinovaVSMilanovIG. Transient mutism and pathologic laughter in the course of cerebellitis. Pediatr Neurol. 2009;41:49–52.
8.
MewasinghLDKadhimHChristopheC. Nonsurgical cerebellar mutism (anarthria) in two children. Pediatr Neurol. 2003;28:59–63.
9.
PapavasiliouASKotsalisCTrakadasS. Transient cerebellar mutism in the course of acute cerebellitis. Pediatric Neurol. 2004;30:71–74.
10.
TakanashiJMiyamotoTAndoN. Clinical and radiological features of rotavirus cerebellitis. AJNR Am J Neuroradiol. 2010;31:1591–1595.
11.
GillD. Postinfectious ataxia and cerebellitis. In: DaleRCVincentA, eds. Inflammatory and Autoimmune Disorders of the Nervous System in Children. 1st ed. London: Mac Keith Press; 2010:190–206.
12.
De BrueckerYClausFDemaerelP. MRI findings in acute cerebellitis. Eur Radiol. 2004;14:1478–1483.
13.
HorowitzMBPangDHirschW. Acute cerebellitis: case report and review. Pediatr Neurosurg. 1991;17:142–145.
14.
ShiiharaTWatanabeMHonmaA. Rotavirus associated acute encephalitis/encephalopathy and concurrent cerebellitis: report of two cases. Brain Dev. 2007;29:670–673.
15.
KobayashiSNegishiYAndoN. Two patients with acute rotavirus encephalitis associated with cerebellar signs and symptoms. Eur J Pediatr. 2010;169:1287–1291.
16.
KubotaTSuzukiTKitaseY. Chronological diffusion-weighted imaging changes and mutism in the course of rotavirus-associated acute cerebellitis/cerebellopathy concurrent with encephalitis/encephalopathy. Brain Dev. 2011;33:21–27.
17.
SiokaCKyritsisAP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63:761–767.
WeissHDWalkerMDWiernikPH. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med. 1974;291:75–81.
20.
WeissHDWalkerMDWiernikPH. Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med. 1974;291:127–133.
21.
ResarLMPhillipsPCKastanMB. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer. 1993;71:117–123.
22.
BakerWJRoyerGLJrWeissRB. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9:679–693.
23.
ModzelewskiRLepretreSMartinaudO. Brain perfusion in adult patients with acute myeloblastic leukemia before and after cytosine arabinoside. Mol Imaging Biol. 2011;13:747–753.
24.
MillerLLinkMPBolognaSParkerBR. Cerebellar atrophy caused by high-dose cytosine arabinoside: CT and MR findings. AJR Am J Roentgenol. 1989;152:343–344.
25.
LazarusHMHerzigRHHerzigGP. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer. 1981;48:2577–2582.
26.
WarrellRPJrBermanE. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4:74–79.
27.
HeltonKJPatayZTriplettBM. Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48:729–731.
AlexanderTBLacayoNJChoiJK. Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia. J Clin Oncol. 2016;34:4094–4101.
30.
PoundCMKeeneDLUdjusKHumphreysPJohnstonDL. Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2007;29:183–186.
31.
KieslichMPortoLLanfermannH. Cerebrovascular complications of l-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003;25:484–487.
32.
HouraniRAbboudMHouraniMKhalifehHMuwakkitS. l-Asparaginase–induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. Neuropediatrics. 2008;39:46–50.
AvramovaBEHristovaTYordanovaM. Cerebellar degeneration as a rare paraneoplastic syndrome in a child with Hodgkin lymphoma. J Pediatr Hematol Oncol. 2016;38:470–472.
